Skye Bioscience Inc (SKYE)

$1.54 +0.09 (6.21%)
Market Cap 44.93M
Revenue (ttm) 0.00
Net Income (ttm) -26.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 625,300
Avg Vol 953,780
Day's Range N/A - N/A
Shares Out 30.99M
Stochastic %K 77%
Beta 2.34
Analysts Strong Sell
Price Target $8.71

Company Profile

Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in Jan...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 410 0266
Address:
11250 El Camino Real, Suite 100, San Diego, United States
OTCMOBSTER
OTCMOBSTER Oct. 24 at 10:47 PM
$BURU $SKYE $CHUC
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Oct. 24 at 2:05 PM
$SKYE Ignore these nonsense posts bashing stocks.... The anger comes from one's that can't read a chart... Nice bounce from $1.31.... $1.53 To break here for a shot at $1.75... Watch it 🚨 🚨
1 · Reply
DanishViking92
DanishViking92 Oct. 24 at 12:04 PM
$SKYE Dont buy into this company - Results where embarrassing bad, management has been talking this drug to the sky and repeatedly talked about early positive mice results and now we have seen the test on humans and it wasnt good enough, placebo effects could be the small effect we saw.. really bad and i bet this stock will go down to pennies and then reverse split once again. Id place my money elsewhere. GL
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 24 at 8:33 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $SKYE Current Share Price: $1.48 Contracts: $SKYE March 20, 2026 $2 Calls Scale in: $0.21- $0.26 Scale out: $0.33-$0.43 Can Easily Capture: 60% ROI Blended DTE: 148 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
OTCMOBSTER
OTCMOBSTER Oct. 23 at 9:48 PM
$IBIO $BOXL $CYBL $SKYE I need a few more nest eggs for retirement, Anyone have some hidden gems i can do DD on?
3 · Reply
BillionerOfKing
BillionerOfKing Oct. 23 at 5:45 PM
$SKYE Current Stock Price: $1.49 Contracts to trade: $2.5 SKYE Nov 21 2025 Call Entry: $0.05 Exit: $0.08 ROI: 68% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 23 at 11:23 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $SKYE Current Share Price: $1.43 Contracts: $SKYE March 20, 2026 $2 Calls Scale in: $0.21- $0.26 Scale out: $0.33-$0.43 Can Easily Capture: 60% ROI Blended DTE: 149 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
OTCMOBSTER
OTCMOBSTER Oct. 23 at 5:45 AM
$SKYE is this still a good price point to enter?
1 · Reply
Ge_ne_tics
Ge_ne_tics Oct. 21 at 10:10 PM
$SKYE is this bottomed yet?
0 · Reply
YazzJr
YazzJr Oct. 20 at 7:53 PM
$SKYE I am hoping this can stay above $1 otherwise we are looking at a some non-compliance issues with the NASDAQ and the last thing shareholders need at this point is a reverse split in order to stay compliant.
1 · Reply
Latest News on SKYE
Skye Bioscience, Inc. - Special Call

Oct 6, 2025, 2:25 PM EDT - 19 days ago

Skye Bioscience, Inc. - Special Call

Nasdaq Jumps Over 150 Points; Skye Bioscience Shares Plunge

Oct 6, 2025, 1:09 PM EDT - 19 days ago

Nasdaq Jumps Over 150 Points; Skye Bioscience Shares Plunge

Skye Bioscience's Investigational Drug Disappoints As Monotherapy For Weight Loss

Oct 6, 2025, 10:39 AM EDT - 19 days ago

Skye Bioscience's Investigational Drug Disappoints As Monotherapy For Weight Loss

Skye Bioscience's obesity drug fails to meet main goal of mid-stage study

Oct 6, 2025, 7:09 AM EDT - 19 days ago

Skye Bioscience's obesity drug fails to meet main goal of mid-stage study

Skye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial

Oct 6, 2025, 7:00 AM EDT - 19 days ago

Skye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial

Skye Bioscience: Promising Nimacimab Data Supports Buy Rating

Oct 1, 2025, 10:45 AM EDT - 24 days ago

Skye Bioscience: Promising Nimacimab Data Supports Buy Rating

Could This New Drug Be The Safer Way To Fight Obesity?

Sep 19, 2025, 2:19 PM EDT - 5 weeks ago

Could This New Drug Be The Safer Way To Fight Obesity?

Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting

Sep 19, 2025, 7:00 AM EDT - 5 weeks ago

Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting

Skye Bioscience, Inc. (SKYE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 9:45 AM EDT - 6 weeks ago

Skye Bioscience, Inc. (SKYE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data

Sep 5, 2025, 1:35 PM EDT - 7 weeks ago

Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data

Skye Bioscience, Inc. (SKYE) Virtual KOL Event Transcript

Sep 5, 2025, 1:30 AM EDT - 7 weeks ago

Skye Bioscience, Inc. (SKYE) Virtual KOL Event Transcript

Skye's CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model

Sep 4, 2025, 7:00 AM EDT - 7 weeks ago

Skye's CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model

Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study

Sep 2, 2025, 7:00 AM EDT - 7 weeks ago

Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study

Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout

Aug 27, 2025, 7:00 AM EDT - 2 months ago

Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout

Skye Bioscience to Participate in Upcoming Investment and Medical Conferences

Aug 21, 2025, 7:00 AM EDT - 2 months ago

Skye Bioscience to Participate in Upcoming Investment and Medical Conferences

Skye Bioscience, Inc. (SKYE) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 8:36 PM EDT - 2 months ago

Skye Bioscience, Inc. (SKYE) Q2 2025 Earnings Call Transcript

Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update

Aug 7, 2025, 4:01 PM EDT - 2 months ago

Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update

Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025

Jul 30, 2025, 7:00 AM EDT - 3 months ago

Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025

Skye Bioscience Partners With Arecor: Potentially Enhanced Nimacimab Dosing

Jul 7, 2025, 11:59 PM EDT - 3 months ago

Skye Bioscience Partners With Arecor: Potentially Enhanced Nimacimab Dosing

Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions

Jun 23, 2025, 7:00 AM EDT - 4 months ago

Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions

Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific Sessions

Jun 17, 2025, 7:00 AM EDT - 4 months ago

Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific Sessions

Skye Bioscience to Participate in Upcoming Investment Conferences

May 22, 2025, 7:00 AM EDT - 5 months ago

Skye Bioscience to Participate in Upcoming Investment Conferences

Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab

May 19, 2025, 5:00 AM EDT - 5 months ago

Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 13, 2025, 4:05 PM EDT - 5 months ago

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity

May 13, 2025, 7:00 AM EDT - 5 months ago

Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity

Skye Bioscience, Inc. (SKYE) Q1 2025 Earnings Call Transcript

May 9, 2025, 7:20 PM EDT - 6 months ago

Skye Bioscience, Inc. (SKYE) Q1 2025 Earnings Call Transcript

Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity

May 8, 2025, 4:01 PM EDT - 6 months ago

Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity

Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025

May 7, 2025, 7:00 AM EDT - 6 months ago

Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025

Skye Bioscience to Participate in May Investment and Medical Conferences

Apr 29, 2025, 7:00 AM EDT - 6 months ago

Skye Bioscience to Participate in May Investment and Medical Conferences

A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value

Apr 16, 2025, 7:50 AM EDT - 6 months ago

A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value

Skye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal Models

Apr 15, 2025, 3:42 PM EDT - 6 months ago

Skye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal Models

LLY

Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model

Apr 15, 2025, 7:00 AM EDT - 6 months ago

Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model

Skye Bioscience to Conduct Meetings at Piper Sandler Conference

Apr 14, 2025, 7:00 AM EDT - 6 months ago

Skye Bioscience to Conduct Meetings at Piper Sandler Conference

Skye Bioscience, Inc. (SKYE) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 9:58 PM EDT - 7 months ago

Skye Bioscience, Inc. (SKYE) Q4 2024 Earnings Call Transcript

Skye Bioscience to Announce 2024 Financial Results on March 20th, 2025

Mar 14, 2025, 7:00 AM EDT - 8 months ago

Skye Bioscience to Announce 2024 Financial Results on March 20th, 2025

Skye Bioscience to Present at TD Cowen Health Care Conference

Feb 20, 2025, 7:00 AM EST - 8 months ago

Skye Bioscience to Present at TD Cowen Health Care Conference

Skye Bioscience Announces Participation in February Conferences

Feb 4, 2025, 7:00 AM EST - 9 months ago

Skye Bioscience Announces Participation in February Conferences

MoneyShow's Best Investment Ideas For 2025: Part 8

Feb 3, 2025, 9:20 AM EST - 9 months ago

MoneyShow's Best Investment Ideas For 2025: Part 8

DELL FNV MNKD MSTR SKE AMSC

Skye Bioscience to Present at J.P. Morgan Healthcare Conference

Dec 19, 2024, 7:00 AM EST - 11 months ago

Skye Bioscience to Present at J.P. Morgan Healthcare Conference

Skye Bioscience: Nimacimab Targets Safer Weight Loss, Speculative Buy

Dec 10, 2024, 8:32 AM EST - 11 months ago

Skye Bioscience: Nimacimab Targets Safer Weight Loss, Speculative Buy

Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor

Nov 14, 2024, 7:00 AM EST - 1 year ago

Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor

Skye Bioscience, Inc. (SKYE) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 10:36 PM EST - 1 year ago

Skye Bioscience, Inc. (SKYE) Q3 2024 Earnings Call Transcript

Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights

Nov 7, 2024, 4:01 PM EST - 1 year ago

Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights

Skye Bioscience to Announce Third Quarter 2024 Results

Nov 1, 2024, 7:00 AM EDT - 1 year ago

Skye Bioscience to Announce Third Quarter 2024 Results

Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences

Oct 21, 2024, 7:00 AM EDT - 1 year ago

Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences

3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn't Ignore

Oct 9, 2024, 1:13 PM EDT - 1 year ago

3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn't Ignore

RENT SCWO

Skye: Moving Weight Loss Drugs To The Next Level

Sep 4, 2024, 11:26 AM EDT - 1 year ago

Skye: Moving Weight Loss Drugs To The Next Level

Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences

Aug 26, 2024, 7:00 AM EDT - 1 year ago

Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences

Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity

Aug 22, 2024, 7:00 AM EDT - 1 year ago

Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity

OTCMOBSTER
OTCMOBSTER Oct. 24 at 10:47 PM
$BURU $SKYE $CHUC
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Oct. 24 at 2:05 PM
$SKYE Ignore these nonsense posts bashing stocks.... The anger comes from one's that can't read a chart... Nice bounce from $1.31.... $1.53 To break here for a shot at $1.75... Watch it 🚨 🚨
1 · Reply
DanishViking92
DanishViking92 Oct. 24 at 12:04 PM
$SKYE Dont buy into this company - Results where embarrassing bad, management has been talking this drug to the sky and repeatedly talked about early positive mice results and now we have seen the test on humans and it wasnt good enough, placebo effects could be the small effect we saw.. really bad and i bet this stock will go down to pennies and then reverse split once again. Id place my money elsewhere. GL
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 24 at 8:33 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $SKYE Current Share Price: $1.48 Contracts: $SKYE March 20, 2026 $2 Calls Scale in: $0.21- $0.26 Scale out: $0.33-$0.43 Can Easily Capture: 60% ROI Blended DTE: 148 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
OTCMOBSTER
OTCMOBSTER Oct. 23 at 9:48 PM
$IBIO $BOXL $CYBL $SKYE I need a few more nest eggs for retirement, Anyone have some hidden gems i can do DD on?
3 · Reply
BillionerOfKing
BillionerOfKing Oct. 23 at 5:45 PM
$SKYE Current Stock Price: $1.49 Contracts to trade: $2.5 SKYE Nov 21 2025 Call Entry: $0.05 Exit: $0.08 ROI: 68% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 23 at 11:23 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $SKYE Current Share Price: $1.43 Contracts: $SKYE March 20, 2026 $2 Calls Scale in: $0.21- $0.26 Scale out: $0.33-$0.43 Can Easily Capture: 60% ROI Blended DTE: 149 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
OTCMOBSTER
OTCMOBSTER Oct. 23 at 5:45 AM
$SKYE is this still a good price point to enter?
1 · Reply
Ge_ne_tics
Ge_ne_tics Oct. 21 at 10:10 PM
$SKYE is this bottomed yet?
0 · Reply
YazzJr
YazzJr Oct. 20 at 7:53 PM
$SKYE I am hoping this can stay above $1 otherwise we are looking at a some non-compliance issues with the NASDAQ and the last thing shareholders need at this point is a reverse split in order to stay compliant.
1 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 20 at 6:49 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $SKYE Current Share Price: $1.38 Contracts: $SKYE March 20, 2026 $2 Calls Scale in: $0.26- $0.32 Scale out: $0.40-$0.52 Can Easily Capture: 60% ROI Blended DTE: 152 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
MarketsParadise
MarketsParadise Oct. 19 at 8:33 PM
$BYND $SPHL $SKYE $BSLK VRME 💎
0 · Reply
LetsGoBflo
LetsGoBflo Oct. 18 at 1:29 PM
$SKYE ok I bailed again. Broke major resistance levels down. Watching for bottom again - company will have to step in soon to protect compliance. I’ll play that pump.
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 17 at 9:43 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $SKYE Current Share Price: $1.45 Contracts: $SKYE March 20, 2026 $2 Calls Scale in: $0.32- $0.39 Scale out: $0.49-$0.63 Can Easily Capture: 60% ROI Blended DTE: 154 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
acarsoy
acarsoy Oct. 17 at 9:07 PM
$SKYE where’s the bottom lol
2 · Reply
MindsTrading
MindsTrading Oct. 17 at 8:04 PM
$SKYE added a little more
0 · Reply
BikerWarrior
BikerWarrior Oct. 17 at 8:00 PM
$SKYE
0 · Reply
HolyShnikes
HolyShnikes Oct. 17 at 4:55 PM
$SKYE any hope here?
2 · Reply
DanishViking92
DanishViking92 Oct. 17 at 9:21 AM
$SKYE come over to $TCRX before it hits $6.. it went from $2 to $2.50 in last couple of days. 2 year results coming soon! New type of cancer treatment, where you use the persons own immune system to eliminate the t-cells!
0 · Reply
DanishViking92
DanishViking92 Oct. 17 at 9:17 AM
$SKYE
0 · Reply
debbiekatz
debbiekatz Oct. 16 at 7:56 PM
$SKYE made new 2 month low today of 1.47. dipped under 1.5 which is where it is now. has not turned up yet at 1.49. i would just watch now for bottom.
0 · Reply
MindsTrading
MindsTrading Oct. 16 at 7:52 PM
$SKYE starter position
0 · Reply